About: No evidence of SARS‐CoV‐2 RNA among blood donors: A multicenter study in Hubei, China

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: No evidence of SARS‐CoV‐2 RNA among blood donors: A multicenter study in Hubei, China Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	No evidence of SARS‐CoV‐2 RNA among blood donors: A multicenter study in Hubei, China
Creator	Li, Yuanyuan Su, Dan Wang, Song Yan, Ying Wang, Lunan Chang, Le Yang, \| Zhao, \| Zhong, \| Deng, Lijuan Fei Guo, \| Hu, Guibin Nie, Xinjiao Peng, Dongju Shouliang Gao, \| Wang, Jundao
Source	Medline; PMC
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) RNA could be detected in the blood of infected cases. From February 9, all blood establishments in Hubei province, China, implemented nucleic acid testing (NAT) for SARS‐CoV‐2 RNA among blood donors to ensure blood safety. STUDY DESIGN AND METHODS: Nucleic acid test screening individually (ID) or by minipool (MP) testing was performed according to the manufacturerʼs instructions. Inactivated culture supernatant of SARS‐CoV‐2–infected Vero cells was quantified by droplet digital polymerase chain reaction (ddPCR) and series diluted with negative plasma to evaluate the assayʼs performance. RESULTS: The limit of detection of the kit for MP testing was 62.94 and 33.14 copies/mL for N and ORF1ab region, respectively. ID testing could achieve 3.87 and 4.85 copies/mL for two regions using 1600 μL of plasma. Coefficients of variations of two different concentrations of reference samples were all less than 5% in MP testing. As of April 30, 2020, a total of 98,342 blood donations including 87,095 whole blood donations and 11,247 platelet donations were tested by ID or MP testing, and no RNAemia was found. In addition, Hubei province suffered precipitously decreased blood supply, especially in February: 86% reduction compared with the same period of 2019. CONCLUSION: Nucleic acid test screening of SARS‐CoV‐2 on blood donations is suitable in blood establishments using the commercial real‐time PCR detection kit based on available instruments. The negative result indicated that SARS‐CoV‐2 appears to be no direct threat to blood safety but raises some serious issues for general blood supply.
has issue date	2020-07-14(xsd:dateTime)
bibo:doi	10.1111/trf.15943
bibo:pmid	32666556
has license	no-cc
sha1sum (hex)	1180cd4da7cbf3d6ee8d082ac87b4195e72f0ba8
schema:url	https://doi.org/10.1111/trf.15943
resource representing a document's title	No evidence of SARS‐CoV‐2 RNA among blood donors: A multicenter study in Hubei, China
has PubMed Central identifier	PMC7404423
has PubMed identifier	32666556
schema:publication	Transfusion
resource representing a document's body	covid:1180cd4da7cbf3d6ee8d082ac87b4195e72f0ba8#body_text
is schema:about of	named entity 'RNA' named entity 'ensure' named entity 'blood donors' named entity 'multicenter' named entity 'IMPLEMENTED' named entity 'Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'RNA' named entity 'acid' named entity 'evidence' named entity 'China' named entity 'Severe acute respiratory syndrome coronavirus 2' named entity 'Hubei' named entity 'blood donors' named entity 'SARS-CoV-2' named entity 'blood center' named entity 'plasma' named entity 'Probit analysis' named entity 'asymptomatic' named entity 'SARS-CoV-2' named entity 'viral load' named entity 'Italy' named entity 'Iran' named entity 'blood supply' named entity 'plasma' named entity 'Hubei' named entity 'SARS-CoV-2' named entity 'emerging infection' named entity 'HCV' named entity 'SARS-CoV-2' named entity 'Hubei' named entity 'histogram' named entity 'Blood Center' named entity 'RNA' named entity 'probability' named entity 'Wuhan' named entity 'FDA' named entity 'virus' named entity 'blood donations' named entity '95% CI' named entity 'serologic' named entity 'Standard deviation' named entity 'viral RNA' named entity 'epidemic' named entity 'virus-like particles' named entity 'Wuhan' named entity 'primers' named entity 'transfusion' named entity 'blood supply' named entity 'Nucleocapsid' named entity 'Blood Center' named entity 'respiratory tract' named entity 'repeatedly tested' named entity 'plasma' named entity 'reverse transcription-polymerase chain reaction' named entity 'Hubei' named entity 'real-time PCR' named entity 'blood supply' named entity 'SARS-CoV-2' named entity 'blood supply' named entity 'Wuhan City' named entity 'plasma' named entity 'Wuhan' named entity 'viral transmission' named entity 'blood supply' named entity 'Hubei Province' named entity 'Nucleocapsid'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software